Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Phase 3 KINECT®-DCP study evaluating the efficacy, safety ...

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Phase 3 KINECT®-DCP study evaluating the efficacy, safety, and tolerability of valbenazine in pediatric and adult participants who ...

In 2003, Medtronic first received a humanitarian green light from the FDA to offer its deep brain stimulation implants to treat the symptoms of dystonia—the painful movement disorder that can cause ...

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has confirmed its initial recommendation to not consider deutetrabenazine as a new active substance. In June this ...

Tardive dyskinesia (TD) can be addressed by the right intervention even in severe, refractory cases. These cases, characterized by involuntary muscle movements, are most often caused by antipsychotics ...

Aim: Dyskinesia is a hyperkinetic abnormal involuntary movement (AIM), like chorea, dystonia, athetosis, and ballism. AIM can occur in Levodopa-induced dyskinesia (LID) in Parkinson's disease (PD), ...

Currently there are two FDA approved treatment options for tardive dyskinesia. There are two medications that are VMAT2 inhibitors. These are valbenazine (Ingrezza) and deutetrabenazine (Austedo) made ...

Tardive dyskinesia is a common side effect caused by antipsychotic use. It is a neurological disorder characterized by involuntary, repetitive movements, often involving the face, mouth, tongue, and ...

Dystonia is a neurological disorder causing involuntary muscle contractions and abnormal postures. Botulinum toxin (e.g., Botox) is the gold-standard, first-line treatment for focal dystonias, which ...

(RTTNews) - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced results from a study of treatment patterns among patients with tardive dyskinesia (TD) ...

As the annual Tardive Dyskinesia Awareness Week begins again, Neurocrine Biosciences is continuing its work to improve understanding of the condition and available treatments. This time around, the ...

After 5 weeks of taking 300 mg of lithium daily, a 76-year-old woman with lurasidone-induced tardive dyskinesia from treatment for Bipolar II Disorder experienced reduced impact, intensity, and ...